TL;DR: The Centers for Medicare & Medicaid Services modified NCD 344 covering autologous cellular immunotherapy treatment (sipuleucel-T / PROVENGE®), with a policy key of 344-v1 effective January 9, 2026. Here's what billing teams need to know.
CMS autologous cellular immunotherapy coverage policy NCD 344 covers sipuleucel-T (PROVENGE®) for castration-resistant, metastatic prostate cancer. The Centers for Medicare & Medicaid Services established national coverage effective June 30, 2011, and this modification — effective January 9, 2026 — reaffirms and updates that framework. This policy does not list specific CPT or HCPCS codes in the published data, so your billing team needs to identify the correct procedure codes through your MAC and existing charge capture protocols.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Autologous Cellular Immunotherapy Treatment — NCD 344 |
| Policy Code | NCD 344 |
| Change Type | Modified |
| Effective Date | January 9, 2026 |
| Impact Level | High |
| Specialties Affected | Medical Oncology, Urology, Infusion/Outpatient Hospital |
| Key Action | Confirm your charge capture and medical necessity documentation align with NCD 344 Medicare criteria for asymptomatic or minimally symptomatic castration-resistant metastatic prostate cancer before billing |
CMS Autologous Cellular Immunotherapy Coverage Criteria and Medical Necessity Requirements 2026
CMS covers sipuleucel-T under NCD 344 Medicare for a specific, narrow patient population. Get the criteria wrong and your claim denial rate will tell you about it fast.
Coverage requires the patient to have asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone refractory) prostate cancer. That's the on-label FDA indication, and CMS hews tightly to it. The policy language says coverage is "reasonable and necessary" under Section 1862(a)(1)(A) of the Social Security Act for this indication — and that phrase is doing real work here. Medical necessity documentation must reflect this exact clinical picture.
The coverage policy became effective for services on or after June 30, 2011. The January 9, 2026 modification updates the governing framework. Any claims for sipuleucel-T billed to Medicare must meet the 2026 criteria as stated in NCD 344 Medicare — not assumptions carried over from prior internal protocols.
Sipuleucel-T is not a standard infusion drug. It's made individually for each patient from his own white blood cells, collected via leukapheresis. The white blood cells are exposed to PA2024 — a molecule that links prostatic acid phosphatase (PAP) with granulocyte/macrophage-colony stimulating factor (GM-CSF) — and then infused back into the patient. The FDA-approved regimen is three doses, each two weeks apart, over a four-week total treatment period.
This multi-step, patient-specific production process has direct billing implications. You're not billing for a drug pulled from a pharmacy shelf. You're billing for leukapheresis, laboratory processing, and infusion — each of which may have a separate billing event and separate documentation requirement. Your charge capture must reflect each step accurately.
On prior authorization: the policy does not explicitly state a prior authorization requirement in the published NCD text. However, given the cost and complexity of sipuleucel-T treatment, many Medicare Advantage plans layer their own prior auth requirements on top of NCD 344. If your patient is in a Medicare Advantage plan, verify prior authorization requirements with that specific plan before scheduling leukapheresis. Don't assume the NCD alone is sufficient.
Reimbursement for sipuleucel-T is among the highest-cost outpatient oncology claims Medicare processes. That means medical necessity documentation gets scrutinized. Make sure your clinical records clearly state the castration-resistant status, metastatic staging, and symptom burden (asymptomatic or minimally symptomatic) before the claim goes out.
CMS Autologous Cellular Immunotherapy Exclusions and Non-Covered Indications
The published NCD 344 policy lists no specific non-covered indications. CMS states "N/A" for nationally non-covered indications.
That sounds clean, but don't read it as a blank check. The coverage is tightly scoped to the on-label FDA indication. Off-label use — such as symptomatic metastatic prostate cancer, non-metastatic castration-resistant prostate cancer, or other cancer types — falls outside what NCD 344 covers. CMS's silence on specific exclusions doesn't mean those uses are covered. It means they're simply not addressed, which defaults to non-coverage under Medicare rules.
If you're seeing orders for sipuleucel-T in patients who don't match the asymptomatic or minimally symptomatic castration-resistant metastatic profile, loop in your compliance officer before billing. The financial exposure on a denied high-cost claim — and the potential for a False Claims Act issue if medical necessity isn't documented — is real.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone refractory) prostate cancer — on-label FDA use | Covered | Not listed in NCD 344 policy data — confirm with MAC | Effective for services on or after June 30, 2011; reaffirmed in 2026 modification |
| Symptomatic metastatic prostate cancer | Not Covered (outside on-label FDA indication) | N/A | Falls outside NCD 344 Medicare scope |
| Non-metastatic castration-resistant prostate cancer | Not Covered (outside on-label FDA indication) | N/A | NCD 344 requires metastatic disease |
| Off-label use in other cancer types | Not Covered | N/A | NCD 344 is specific to prostate cancer; off-label indications not addressed |
CMS Autologous Cellular Immunotherapy Billing Guidelines and Action Items 2026
The complexity here is real. Sipuleucel-T billing spans multiple distinct clinical events — leukapheresis, laboratory processing, and infusion — and each one needs its own billing footprint. Here's what to do before January 9, 2026.
| # | Action Item |
|---|---|
| 1 | Audit your charge capture for the full sipuleucel-T treatment cycle. The FDA-approved regimen is three infusions, each two weeks apart. Each infusion event is a separate billing encounter. Confirm your charge capture system creates a distinct claim for each of the three treatment doses — not a single bundled claim. |
| 2 | Confirm the correct codes with your MAC. NCD 344 Medicare does not publish specific CPT or HCPCS codes in its current policy data. Contact your Medicare Administrative Contractor to confirm which procedure codes apply to leukapheresis, the infusion of sipuleucel-T, and any related evaluation and management services. Do this before January 9, 2026. |
| 3 | Tighten your medical necessity documentation template. Every claim needs clinical documentation that explicitly states: castration-resistant status, metastatic staging, and that the patient is asymptomatic or minimally symptomatic. Create or update a documentation checklist that your oncology team completes before the first leukapheresis session. |
| 4 | Verify prior authorization requirements for Medicare Advantage patients separately. NCD 344 governs traditional Medicare. Medicare Advantage plans set their own prior auth rules. Pull the plan's coverage policy for each Medicare Advantage patient before scheduling treatment. A missing prior auth is a guaranteed claim denial. |
| 5 | Check your billing guidelines for outpatient hospital versus physician services. This coverage policy applies to two benefit categories: Outpatient Hospital Services Incident to a Physician's Service, and Physicians' Services. If you're billing in an outpatient hospital setting, confirm that your facility and professional fee claims are coordinated correctly and not duplicating billing elements. |
| 6 | Talk to your compliance officer if you have any patients who fall outside the narrow coverage criteria. The cost of sipuleucel-T means a denied claim is a significant write-off. A claim for a patient who doesn't meet the on-label indication is worse — it's a potential compliance issue. When in doubt, get a second opinion internally before the claim goes out. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Autologous Cellular Immunotherapy Under NCD 344
Covered Codes
The published NCD 344 policy data does not list specific CPT or HCPCS codes. This is not unusual for older NCDs that predate detailed code-level policy publishing. You still need the right codes to bill — here's how to get them.
Contact your MAC directly and ask for the covered codes under NCD 344 for sipuleucel-T. Common billing components for this treatment include leukapheresis (the blood cell collection procedure), the infusion of the processed cellular product, and any associated physician evaluation and management. Each of those clinical steps maps to a distinct code set, and your MAC is the authoritative source for NCD 344 Medicare code assignments.
Do not use codes not confirmed through your MAC or a qualified billing consultant. Billing with incorrect codes — even for a clearly covered indication — creates remittance remark codes that trigger manual review, slow reimbursement, and can flag your claims for post-payment audit.
Key ICD-10-CM Diagnosis Codes
The policy data does not publish specific ICD-10-CM codes. Your diagnosis coding for sipuleucel-T claims should reflect:
- Metastatic castration-resistant prostate cancer (hormone refractory)
- Asymptomatic or minimally symptomatic disease burden
Work with your oncology coders to confirm the ICD-10-CM codes that map to this specific clinical picture. The diagnosis code must align precisely with the NCD 344 coverage criteria — "metastatic" and "castration-resistant" need to be in the record and on the claim.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.